simvastatin + placebo

Simvastatin + placebo refers to a specific control arm used in a randomized, double-blind, crossover clinical trial conducted by Provident Clinical Research. This regimen was designed to evaluate the efficacy of adding prescription omega-3-acid ethyl esters (Omacor) to statin therapy in patients with mixed dyslipidemia. Subjects in this arm received 20 mg of simvastatin daily along with four matching placebo capsules. Simvastatin is a statin that lowers LDL cholesterol and other lipid parameters by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in the cholesterol biosynthetic pathway. The trial demonstrated that the addition of omega-3 fatty acids was superior to the simvastatin plus placebo combination in reducing non-HDL cholesterol and triglycerides.

Other names

simvastatin plus placebosimvastatin 20 mg plus placebosimvastatin20 mg plus placebosimvastatin-20 mg plus placebo